BioAge Labs (BIOA)
BioAge Labs on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
3.4M
Short interest
settlement 2026-10-15
3.7
Days to cover
-0.3 days vs prior
50.4%
Short share of volume
2026-11-02
9,800
Fails to deliver
settlement 2026-10-13
Thu 5 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in BIOA is 3,431,572 shares, up 357,596 shares over the last month. Over the last 48 readings it ranged from 428,186 shares (14 November 2025) to 3,744,445 shares (30 June 2026). The latest reading sits at the top of that range. At the reported average volume of 932K shares a day that is 3.7 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/bioa" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 3,431,572 | +4.8% | 932,308 | 3.68 |
| 2026-09-30 | 3,274,379 | +6.5% | 830,478 | 3.94 |
| 2026-09-15 | 3,073,976 | +12.9% | 506,919 | 6.06 |
| 2026-08-31 | 2,722,576 | +22.8% | 577,222 | 4.72 |
| 2026-08-14 | 2,217,521 | -13.6% | 1,159,638 | 1.91 |
| 2026-07-31 | 2,565,606 | +4.7% | 1,360,827 | 1.89 |
| 2026-07-15 | 2,451,099 | -34.5% | 540,360 | 4.54 |
| 2026-06-30 | 3,744,445 | +87.9% | 932,909 | 4.01 |
| 2026-06-15 | 1,992,676 | +11.3% | 383,084 | 5.20 |
| 2026-05-29 | 1,789,687 | +4.8% | 474,182 | 3.77 |
| 2026-05-15 | 1,708,334 | -9.3% | 372,464 | 4.59 |
| 2026-04-30 | 1,884,632 | +8.0% | 430,449 | 4.38 |
| 2026-04-15 | 1,745,467 | +11.9% | 333,358 | 5.24 |
| 2026-03-31 | 1,559,461 | +15.5% | 685,555 | 2.27 |
| 2026-03-13 | 1,350,660 | +5.8% | 519,662 | 2.60 |
| 2026-02-27 | 1,276,379 | -4.9% | 471,563 | 2.71 |
| 2026-02-13 | 1,341,664 | +47.6% | 644,382 | 2.08 |
| 2026-01-30 | 909,129 | -16.3% | 919,863 | 1.00 |
| 2026-01-15 | 1,085,882 | +82.2% | 1,128,484 | 1.00 |
| 2025-12-31 | 596,127 | +6.8% | 316,633 | 1.88 |
| 2025-12-15 | 558,100 | +10.9% | 592,070 | 1.00 |
| 2025-11-28 | 502,999 | +17.5% | 230,155 | 2.19 |
| 2025-11-14 | 428,186 | -7.6% | 286,338 | 1.50 |
| 2025-10-31 | 463,626 | -33.1% | 902,902 | 1.00 |
| 2025-10-15 | 692,983 | -72.2% | 185,023 | 3.75 |
| 2025-09-30 | 2,493,267 | +6.7% | 205,531 | 12.13 |
| 2025-09-15 | 2,337,743 | +0.1% | 176,481 | 13.25 |
| 2025-08-29 | 2,334,511 | -2.8% | 173,215 | 13.48 |
| 2025-08-15 | 2,401,699 | +0.7% | 103,492 | 23.21 |
| 2025-07-31 | 2,385,509 | +3.3% | 89,685 | 26.60 |
| 2025-07-15 | 2,310,277 | -0.3% | 141,085 | 16.38 |
| 2025-06-30 | 2,316,366 | +63.5% | 467,356 | 4.96 |
| 2025-06-13 | 1,416,911 | -10.5% | 456,713 | 3.10 |
| 2025-05-30 | 1,582,903 | -9.2% | 187,484 | 8.44 |
| 2025-05-15 | 1,743,773 | -3.2% | 169,563 | 10.28 |
| 2025-04-30 | 1,801,140 | +4.4% | 269,607 | 6.68 |
| 2025-04-15 | 1,725,418 | -3.4% | 447,739 | 3.85 |
| 2025-03-31 | 1,786,645 | +1.9% | 196,438 | 9.10 |
| 2025-03-14 | 1,752,940 | -5.4% | 122,741 | 14.28 |
| 2025-02-28 | 1,853,512 | -7.0% | 177,491 | 10.44 |
| 2025-02-14 | 1,993,898 | +13.8% | 198,434 | 10.05 |
| 2025-01-31 | 1,751,871 | -14.9% | 285,615 | 6.13 |
| 2025-01-15 | 2,058,583 | +0.0% | 450,598 | 4.57 |
| 2024-12-31 | 2,058,372 | +52.3% | 1,509,462 | 1.36 |
| 2024-12-13 | 1,351,161 | -44.0% | 1,793,136 | 1.00 |
| 2024-11-29 | 2,411,265 | +1.6% | 184,829 | 13.05 |
| 2024-11-15 | 2,372,884 | +7.5% | 214,229 | 11.08 |
| 2024-10-31 | 2,206,479 | +126.7% | 326,619 | 6.76 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of BIOA volume is 50.4%, down 3.2 points over the last five sessions. Over the last 30 readings it ranged from 17.6% (6 October 2026) to 60.1% (30 September 2026). The latest reading is 8.3 points above the 30-session average of 42.1%, on 247K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 125K | 247K | 50.4% | 0 |
| 2026-10-30 | 135K | 350K | 38.7% | 0 |
| 2026-10-29 | 124K | 458K | 27.0% | 0 |
| 2026-10-28 | 216K | 671K | 32.2% | 792 |
| 2026-10-27 | 108K | 482K | 22.5% | 0 |
| 2026-10-26 | 116K | 216K | 53.6% | 6 |
| 2026-10-23 | 96K | 188K | 51.2% | 50 |
| 2026-10-22 | 84K | 197K | 42.8% | 0 |
| 2026-10-21 | 64K | 191K | 33.3% | 0 |
| 2026-10-20 | 231K | 555K | 41.6% | 0 |
| 2026-10-19 | 128K | 447K | 28.6% | 12,776 |
| 2026-10-16 | 141K | 322K | 43.9% | 100 |
| 2026-10-15 | 97K | 289K | 33.7% | 28 |
| 2026-10-14 | 102K | 209K | 48.7% | 27 |
| 2026-10-13 | 128K | 230K | 55.7% | 53 |
| 2026-10-12 | 94K | 176K | 53.5% | 0 |
| 2026-10-09 | 121K | 270K | 44.7% | 0 |
| 2026-10-08 | 106K | 273K | 38.8% | 0 |
| 2026-10-07 | 137K | 270K | 50.8% | 0 |
| 2026-10-06 | 231K | 1.3M | 17.6% | 101 |
| 2026-10-05 | 156K | 326K | 47.8% | 0 |
| 2026-10-02 | 134K | 289K | 46.4% | 0 |
| 2026-10-01 | 96K | 178K | 53.6% | 0 |
| 2026-09-30 | 127K | 211K | 60.1% | 0 |
| 2026-09-29 | 62K | 133K | 47.1% | 1,328 |
| 2026-09-28 | 113K | 355K | 31.8% | 0 |
| 2026-09-25 | 111K | 244K | 45.6% | 22 |
| 2026-09-24 | 128K | 400K | 32.0% | 2,403 |
| 2026-09-23 | 123K | 279K | 44.2% | 0 |
| 2026-09-22 | 186K | 421K | 44.2% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 13 October 2026, the fails-to-deliver balance in BIOA is 9,800 shares, up 7,045 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (1 April 2026) to 12,073 shares (27 July 2026).
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-13 | 9,800 | $5.94 | $58K |
| 2026-10-01 | 2,755 | $7.09 | $20K |
| 2026-09-28 | 6,476 | $7.05 | $46K |
| 2026-09-23 | 62 | $8.46 | $525 |
| 2026-09-18 | 548 | $8.09 | $4K |
| 2026-09-17 | 6 | $7.75 | $47 |
| 2026-09-15 | 28 | $8.48 | $237 |
| 2026-09-04 | 434 | $9.50 | $4K |
| 2026-08-21 | 772 | $9.69 | $7K |
| 2026-08-20 | 666 | $10.75 | $7K |
| 2026-07-27 | 12,073 | $21.77 | $263K |
| 2026-07-21 | 1,301 | $22.32 | $29K |
| 2026-07-16 | 1 | $22.70 | $23 |
| 2026-07-07 | 199 | $24.84 | $5K |
| 2026-06-29 | 1,662 | $23.76 | $39K |
| 2026-06-15 | 40 | $18.04 | $722 |
| 2026-05-28 | 114 | $16.95 | $2K |
| 2026-05-27 | 12 | $16.20 | $194 |
| 2026-05-20 | 474 | $16.37 | $8K |
| 2026-05-19 | 4,150 | $15.34 | $64K |
| 2026-05-05 | 44 | $16.62 | $731 |
| 2026-04-20 | 11 | $18.49 | $203 |
| 2026-04-17 | 318 | $16.99 | $5K |
| 2026-04-15 | 1,666 | $16.57 | $28K |
| 2026-04-14 | 1,000 | $16.19 | $16K |
| 2026-04-06 | 143 | $17.50 | $3K |
| 2026-04-01 | 1 | $17.49 | $17 |
| 2026-03-26 | 10 | $16.41 | $164 |
| 2026-03-25 | 1,978 | $16.11 | $32K |
| 2026-03-24 | 5,474 | $18.63 | $102K |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for BIOA in the last 90 days. The most recent filings are listed below. Latest filing: Barton Shane (Principal Accounting Officer) on 2026-06-30.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | Barton Shane | Principal Accounting Officer | Sell | 20K | $25.19 | $509K | 0 |
| 2026-06-30 | Barton Shane | Principal Accounting Officer | Exercise or conversion | 8K | $4.38 | $34K | 20K |
| 2026-06-30 | Barton Shane | Principal Accounting Officer | Exercise or conversion | 4K | $4.30 | $17K | 12K |
| 2026-06-30 | Barton Shane | Principal Accounting Officer | Exercise or conversion | 4K | $8.39 | $34K | 8K |
| 2026-06-30 | Barton Shane | Principal Accounting Officer | Exercise or conversion | 4K | $10.85 | $47K | 4K |
| 2026-06-29 | Barton Shane | Principal Accounting Officer | Sell | 42K | $25.21 | $1.1M | 0 |
| 2026-06-29 | Barton Shane | Principal Accounting Officer | Exercise or conversion | 14K | $4.38 | $62K | 42K |
| 2026-06-29 | Barton Shane | Principal Accounting Officer | Exercise or conversion | 9K | $4.30 | $39K | 28K |
| 2026-06-29 | Barton Shane | Principal Accounting Officer | Exercise or conversion | 7K | $8.39 | $61K | 19K |
| 2026-06-29 | Barton Shane | Principal Accounting Officer | Exercise or conversion | 9K | $10.85 | $101K | 12K |
| 2026-04-23 | GOLDSTEIN DOV A MD | Chief Financial Officer | Exercise or conversion | 4K | $4.38 | $16K | 37K |
| 2026-04-01 | RUBIN PAUL D | Chief Medical Officer | Sell | 9K | $17.81 | $157K | 0 |
| 2026-04-01 | RUBIN PAUL D | Chief Medical Officer | Exercise or conversion | 3K | $6.57 | $22K | 9K |
| 2026-04-01 | RUBIN PAUL D | Chief Medical Officer | Exercise or conversion | 5K | $4.11 | $22K | 5K |
| 2026-03-02 | RUBIN PAUL D | Chief Medical Officer | Sell | 7K | $20.30 | $151K | 0 |
| 2026-03-02 | RUBIN PAUL D | Chief Medical Officer | Exercise or conversion | 2K | $6.57 | $13K | 7K |
| 2026-03-02 | RUBIN PAUL D | Chief Medical Officer | Exercise or conversion | 5K | $4.11 | $22K | 5K |
| 2026-03-01 | GOLDSTEIN DOV A MD | Chief Financial Officer | Exercise or conversion | 4K | $4.38 | $16K | 33K |
| 2026-02-02 | RUBIN PAUL D | Chief Medical Officer | Sell | 7K | $18.75 | $139K | 0 |
| 2026-02-02 | RUBIN PAUL D | Chief Medical Officer | Exercise or conversion | 2K | $6.57 | $13K | 7K |
| 2026-02-02 | RUBIN PAUL D | Chief Medical Officer | Exercise or conversion | 5K | $4.11 | $22K | 5K |
| 2026-02-01 | GOLDSTEIN DOV A MD | Chief Financial Officer | Exercise or conversion | 4K | $4.38 | $16K | 29K |
| 2026-01-16 | GOLDSTEIN DOV A MD | Chief Financial Officer | Exercise or conversion | 4K | $4.38 | $16K | 26K |
| 2026-01-13 | Fortney Kristen | Chief Executive Officer | Sell | 233K | $18.12 | $4.2M | 977K |
| 2026-01-13 | GOLDSTEIN DOV A MD | Chief Financial Officer | Sell | 2K | $21.08 | $41K | 22K |
| 2026-01-13 | GOLDSTEIN DOV A MD | Chief Financial Officer | Sell | 12K | $20.54 | $240K | 24K |
| 2026-01-13 | GOLDSTEIN DOV A MD | Chief Financial Officer | Sell | 4K | $19.45 | $86K | 36K |
| 2026-01-13 | GOLDSTEIN DOV A MD | Chief Financial Officer | Sell | 9K | $18.43 | $165K | 40K |
| 2026-01-13 | GOLDSTEIN DOV A MD | Chief Financial Officer | Exercise or conversion | 27K | $8.39 | $227K | 49K |
| 2026-01-02 | RUBIN PAUL D | Chief Medical Officer | Sell | 7K | $12.85 | $95K | 0 |
| 2026-01-02 | RUBIN PAUL D | Chief Medical Officer | Exercise or conversion | 2K | $6.57 | $13K | 7K |
| 2026-01-02 | RUBIN PAUL D | Chief Medical Officer | Exercise or conversion | 5K | $4.11 | $22K | 5K |
| 2025-12-09 | RUBIN PAUL D | Chief Medical Officer | Sell | 18K | $12.00 | $216K | 0 |
| 2025-12-09 | RUBIN PAUL D | Chief Medical Officer | Exercise or conversion | 18K | $6.57 | $118K | 18K |
| 2025-12-04 | RUBIN PAUL D | Chief Medical Officer | Sell | 69K | $10.19 | $702K | 0 |
| 2025-12-04 | RUBIN PAUL D | Chief Medical Officer | Exercise or conversion | 69K | $4.11 | $283K | 69K |
| 2024-10-03 | Pande Vijay Satyanand | Director | Buy | 25K | $19.90 | $504K | 1.1M |
| 2024-10-02 | Pande Vijay Satyanand | Director | Buy | 67K | $19.73 | $1.3M | 1.1M |
| 2024-10-01 | Pande Vijay Satyanand | Director | Buy | 127K | $19.73 | $2.5M | 1.0M |
| 2024-09-27 | Barton Shane | Principal Accounting Officer | Buy | 3K | $18.00 | $47K | 3K |
| 2024-09-27 | Hemrajani Rekha | Director | Buy | 3K | $18.00 | $54K | 3K |
| 2024-09-27 | Chen Bihua | Other | Conversion | 1.2M | price not stated in the filing | not stated | 1.2M |
| 2024-09-27 | Chen Bihua | Other | Buy | 450K | $18.00 | $8.1M | 1.6M |
| 2024-09-27 | HEALY JAMES | Director | Buy | 11K | $18.00 | $200K | 11K |
| 2024-09-27 | HEALY JAMES | Director | Buy | 22K | $18.00 | $393K | 22K |
| 2024-09-27 | HEALY JAMES | Director | Buy | 18K | $18.00 | $330K | 18K |
| 2024-09-27 | HEALY JAMES | Director | Buy | 26K | $18.00 | $477K | 26K |
| 2024-09-27 | HEALY JAMES | Director | Buy | 589K | $18.00 | $10.6M | 2.2M |
| 2024-09-27 | HEALY JAMES | Director | Conversion | 1.6M | price not stated in the filing | not stated | 1.6M |
| 2024-09-27 | ENRIGHT PATRICK G | Director | Buy | 400K | $18.00 | $7.2M | 1.7M |
| 2024-09-27 | ENRIGHT PATRICK G | Director | Conversion | 1.3M | price not stated in the filing | not stated | 1.3M |
| 2024-09-27 | Pande Vijay Satyanand | Director | Conversion | 655K | price not stated in the filing | not stated | 655K |
| 2024-09-27 | Pande Vijay Satyanand | Director | Conversion | 856K | price not stated in the filing | not stated | 856K |
| 2024-09-27 | Pande Vijay Satyanand | Director | Conversion | 413K | price not stated in the filing | not stated | 1.3M |
| 2024-09-27 | Pande Vijay Satyanand | Director | Buy | 900K | $18.00 | $16.2M | 900K |
| 2024-09-27 | Pande Vijay Satyanand | Director | Conversion | 190K | price not stated in the filing | not stated | 190K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON10 Form 144 notices on file for BIOA worth $7.8M at the prices reported; 0 in the last 90 days worth $0. Latest: Barton Shane filed on 2026-06-30 to sell 20,216 shares ($509K) from 2026-06-30.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-06-30 | Barton ShaneOfficer | 20K | $509K | 0.045% | 2026-06-30 | Fidelity Brokerage Services LLC |
| 2026-06-29 | Barton ShaneOfficer | 42K | $1.1M | 0.095% | 2026-06-29 | Fidelity Brokerage Services LLC |
| 2026-04-01 | RUBIN PAUL DOfficer | 9K | $157K | 0.020% | 2026-04-01 | Fidelity Brokerage Services LLC |
| 2026-03-02 | RUBIN PAUL DOfficer | 7K | $149K | 0.021% | 2026-03-02 | Fidelity Brokerage Services LLC |
| 2026-02-02 | RUBIN PAUL DOfficer | 7K | $139K | 0.021% | 2026-02-02 | Fidelity Brokerage Services LLC |
| 2026-01-13 | Fortney Kristen10% Stockholder | 233K | $4.2M | 0.650% | 2026-01-13 | RAYMOND JAMES & ASSOCIATES |
| 2026-01-13 | GOLDSTEIN DOV A MDOfficer | 27K | $532K | 0.075% | 2026-01-13 | Fidelity Brokerage Services LLC |
| 2026-01-02 | RUBIN PAUL DOfficer | 7K | $100K | 0.021% | 2026-01-02 | Fidelity Brokerage Services LLC |
| 2025-12-09 | RUBIN PAUL DOfficer | 18K | $216K | 0.050% | 2025-12-09 | Fidelity Brokerage Services LLC |
| 2025-12-04 | RUBIN PAUL DOfficer | 69K | $702K | 0.192% | 2025-12-04 | Fidelity Brokerage Services LLC |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON4 holders report 5% or more of BIOA in their latest filing, all on Schedule 13G (passive). The largest reported stake is Kristen Fortney at 7.2% of the class (2,704,736 shares), filed 2026-02-13 for an event on 2025-12-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-14 | 13G/Ano. 4 | Cormorant Asset Management, LPinvestment adviser, partnership | 2.4M | 5.4% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 4 | Bihua Chenparent holding company, individual | 2.4M | 5.4% | 2026-06-30 |
| 2026-05-15 | 13G/Ano. 1 | VK Services, LLCother entity | 1.8M | 4.0% | 2026-05-15 |
| 2026-05-15 | 13G/Ano. 1 | Vinod Khoslaindividual | 1.8M | 4.0% | 2026-05-15 |
| 2026-05-15 | 13G/Ano. 1 | Khosla Ventures Opportunity Associates I, LLCother entity | 1.4M | 3.1% | 2026-05-15 |
| 2026-05-15 | 13G/Ano. 1 | Khosla Ventures Opportunity I, LPpartnership | 1.4M | 3.1% | 2026-05-15 |
| 2026-05-15 | 13G/Ano. 1 | Khosla Ventures Associates VI, LLCother entity | 437K | 1.0% | 2026-05-15 |
| 2026-05-15 | 13G/Ano. 1 | Khosla Ventures VI, LPpartnership | 437K | 1.0% | 2026-05-15 |
| 2026-04-27 | 13G | BlackRock, Inc.parent holding company | 2.2M | 5.0% | 2026-03-31 |
| 2026-02-17 | 13G/Ano. 1 | ADAR1 Capital Management, LLCinvestment adviser, other entity | 136K | 0.4% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | Daniel Schneebergerparent holding company, individual | 136K | 0.4% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 1 | Kristen Fortneyindividual | 2.7M | 7.2% | 2025-12-31 |
13F holders
Tracked managers holding BIOA at their latest 13F. JSON6 of the 30 tracked managers held BIOA at their latest 13F, $32.4M in total at quarter-end prices. D. E. Shaw & Co. is the largest at $18.2M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 4 added shares and 2 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| D. E. Shaw & Co. | 2026-06-30 | 743K | $18.2M | 0.01% | +44K |
| Millennium Management | 2026-06-30 | 223K | $5.5M | 0.00% | -208K |
| Renaissance Technologies | 2026-06-30 | 166K | $4.1M | 0.01% | +27K |
| Citadel Advisors | 2026-06-30 | 78K | $1.9M | 0.00% | new |
| Two Sigma Investments | 2026-06-30 | 61K | $1.5M | 0.00% | +14K |
| AQR Capital Management | 2026-06-30 | 51K | $1.3M | 0.00% | -18K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
BioAge Labs in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows BioAge Labs (BIOA), SEC CIK 1709941, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-13.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-06-30.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-14.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-05.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-06-30.JSON and CSV
- Company record
- EDGAR filing index for CIK 1709941Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of BIOA is sold short?
3,431,572 shares were held short at the 2026-10-15 settlement, 3.7 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is BIOA's daily short volume?
On 2026-11-02, 124,531 of the 247,113 BIOA shares reported to FINRA were sold short, 50.4% of the day's reported volume. Short volume is a flow for one day, not a position.
Does BIOA have fails to deliver?
The SEC's latest file shows 9,800 BIOA shares failed to deliver at settlement 2026-10-13. Fails are reported per settlement date and published twice a month with a lag.
Are BIOA insiders buying or selling?
No open-market insider trades were reported for BIOA in the last 90 days. The most recent filings are listed below. Latest filing: Barton Shane (Principal Accounting Officer) on 2026-06-30.
Have BIOA insiders filed to sell?
10 Form 144 notices on file for BIOA worth $7.8M at the prices reported; 0 in the last 90 days worth $0. Latest: Barton Shane filed on 2026-06-30 to sell 20,216 shares ($509K) from 2026-06-30.
Who owns 5% or more of BIOA?
4 holders report 5% or more of BIOA in their latest filing, all on Schedule 13G (passive). The largest reported stake is Kristen Fortney at 7.2% of the class (2,704,736 shares), filed 2026-02-13 for an event on 2025-12-31.
Which tracked 13F managers own BIOA?
6 of the 30 tracked 13F managers held BIOA shares at their latest filing, $32.4M in all. The largest: D. E. Shaw & Co. (743K shares, $18.2M), Izzy Englander's Millennium Management (223K shares, $5.5M), Renaissance Technologies (166K shares, $4.1M), Ken Griffin's Citadel Advisors (78K shares, $1.9M), Two Sigma Investments (61K shares, $1.5M), Cliff Asness's AQR Capital Management (51K shares, $1.3M).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.